NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘biopharmaceuticals’

16 February 2016

Cormorant, Hillhouse, venBio co-lead $47.1m round for Apellis

pills-943764_1280 Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund came in as new investors in a $47.1m Series D round for Apellis Pharmaceuticals.

23 December 2015

Altitude Life Science leads $40m Series B round in eFFECTOR Therapeutics

bacteria-811861_1920 Venture capital investor Altitude Life Science Ventures has led a $40m financing round for San Diego-based biopharmaceutical company eFFECTOR Therapeutics.

9 July 2014

Remiges Biopharma nears halfway mark for debut fund $

bio Biopharmaceutical venture capital firm Remiges Biopharma, which was recently launched by former Mitsui executives, is nearing the halfway mark in its debut fundraise, AltAssets can reveal.

4 June 2014

Deerfield backs KemPharm with $60m investment

biotech_lrg Healthcare-focused investment firm Deerfield Management Company has backed clinical stage biopharmaceutical company KemPharm with a $60m investment.

27 May 2014

UPDATE: FreshTracks nears final close for third fund $

FreshTracks Venture capital firm FreshTracks Capital is set to close its third fund on June 30, according to a person with direct knowledge of the matter.

21 May 2014

Venture capital-backed Kite Pharma files for IPO

cancer band pink_sq Venture capital-backed biopharmaceutical startup Kite Pharma has filed for an IPO.

23 April 2014

OrbiMed leads $22m round for Aerpio Therapeutics

biotech_lrg Biopharmaceutical startup Aerpio Therapeutics has secured $22m in a round led by venture capital firm OrbiMed.

17 April 2014

Venture capital-backed Epirus raises $36m, merges with Nasdaq-listed Zalicus

biotech_lrg Boston-based startup Epirus Biopharmaceuticals has secured $36m in a Series B round led by Livzon Mabpharm and agreed to merge with Nasdaq-listed group Zalicus.

13 March 2014

OrbiMed helps Sage Therapeutics raise $38m

medical monitor Healthcare-focused investment firm OrbiMed Advisors participated in a $38m Series C round for biopharmaceutical company Sage Therapeutics.

7 February 2014

Venture capital-backed Auspex prices IPO at $12 per share

shares stocks IPO Venture capital-backed biopharmaceutical company Auspex Pharmaceuticals has priced its IPO on the Nasdaq exchange at $12 per share.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016